CG001 prevented PNH erythrocytes from hemolysis. (A-B) CG001 protected human PNH erythrocytes from CP- and AP-induced hemolysis. Hemolysis and C3b/iC3b deposition (selective for CP) in CD59⁻ PNH erythrocytes were induced by (A) CP or (B) AP activation, which could be effectively prevented by CG001 treatment. However, (A) eculizumab treatment prevented only hemolysis but not C3b/iC3b deposition induced by CP activation and (B) showed little effect on AP-induced hemolysis. (C-J) CG001 blocked both IVH and EVH in the NHS-induced and AP-mediated hemolytic mouse models compared with eculizumab and iptacopan. (C,G) IVH was determined by the plasma images, and (D,H) the quantitative plasma hemoglobin. (E,I) EVH was represented by the deposition of C3b/iC3b in erythrocytes, which is shown as a scatterplot, and (F,J) the related quantitative results. (C-F) CG001, and (G-J) eculizumab and iptacopan. Data are presented as mean ± standard error of the mean (SEM); n = 4; ∗P < .05 and ∗∗∗∗P < .0001.